Mulazzani, Elisabeth
Kong, Klara
Aróstegui, Juan I. http://orcid.org/0000-0003-4757-504X
Ng, Ashley P. http://orcid.org/0000-0001-9690-0879
Ranathunga, Nishika
Abeysekera, Waruni http://orcid.org/0000-0002-3110-8984
Garnham, Alexandra L.
Ng, Sze-Ling
Baker, Paul J.
Jackson, Jacob T. http://orcid.org/0000-0002-6396-2739
Lich, John D.
Hibbs, Margaret L.
Wicks, Ian P. http://orcid.org/0000-0001-7050-6822
Louis, Cynthia http://orcid.org/0000-0001-8382-6358
Masters, Seth L. http://orcid.org/0000-0003-4763-576X
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (2003159, 2003756, 1154325, 1113577)
Wellcome Trust (208694/Z/17/Z)
Sylvia and Charles Viertel Charitable Foundation (VTL2016F027)
Veski (VIF 14)
Deutsche Forschungsgemeinschaft (SCHU 3126/ 3-1)
EC | European Regional Development Fund (PID2021-125106OB-C31)
Article History
Received: 3 September 2022
Accepted: 22 February 2023
First Online: 30 March 2023
Competing interests
: S.L.M. is a Scientific Advisor for Odyssey Therapeutics and NRG Therapeutics. S.-L.N. and J.N. are employees of GSK. I.P.W. has acted as a Scientific Advisor for CSL and received funding for research on G-CSF antagonism in inflammatory diseases. All other authors declare no competing interests.